Cogent Biosciences, Inc.

NasdaqGS:COGT 株式レポート

時価総額：US$1.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cogent Biosciences マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Andy Robbins

最高経営責任者

US$7.9m

報酬総額

CEO給与比率8.3%
CEO在任期間3.9yrs
CEOの所有権n/a
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間4.2yrs

経営陣の近況

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 27
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 20
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17
What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

CEO報酬分析

Cogent Biosciences の収益と比較して、Andy Robbins の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

報酬と市場: Andyの 総報酬 ($USD 7.90M ) は、 US市場 ($USD 3.40M ) の同規模の企業の平均を上回っています。

報酬と収益: Andyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Andy Robbins (48 yo)

3.9yrs

在職期間

US$7,898,772

報酬

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Andrew Robbins
President3.9yrsUS$7.90mデータなし
John Robinson
Chief Scientific Officer3.4yrsUS$2.98m0%
$ 0
Jessica Sachs
Chief Medical Officer5.3yrsUS$3.00m0.0012%
$ 14.1k
John Green
CFO & Principal Accounting Officer4.2yrsUS$2.14mデータなし
Brad Barnett
Chief Technology Officer3.8yrsデータなしデータなし
Christi Waarich
Senior Director of Investor Relationsno dataデータなしデータなし
Evan Kearns
Chief Legal Officer & Corporate Secretary3.3yrsデータなしデータなし
Erin Schellhammer
Chief People Officerno dataデータなしデータなし
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno dataデータなしデータなし
Brad Fell
Senior Vice President of Chemistryno dataデータなしデータなし
Rachael Easton
VP & Head of Clinical Development1.8yrsデータなしデータなし
Ben Exter
Senior VP and Head of Regulatory & Pharmacovigilanceless than a yearデータなしデータなし

3.6yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: COGTの経営陣は 経験豊富 であると考えられます ( 3.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Andrew Robbins
President3.9yrsUS$7.90mデータなし
Arlene Morris
Independent Director5.2yrsUS$345.49k0%
$ 0
Matthew Ros
Independent Director5.2yrsUS$336.69k0%
$ 0
Todd Shegog
Independent Director3.6yrsUS$345.80k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno dataデータなしデータなし
Karen Jean Ferrante
Independent Director6.6yrsUS$340.37k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno dataデータなしデータなし
Ryan Corcoran
Member of Scientific Advisory Boardno dataデータなしデータなし
Christopher Cain
Independent Director4.2yrsUS$341.36k0%
$ 0
Peter Harwin
Independent Chairman of the Board4.2yrsUS$364.55k0%
$ 0
Srdan Verstovsek
Member of Scientific Advisory Boardno dataデータなしデータなし
Sylvia Adams
Member of Scientific Advisory Board1.7yrsデータなしデータなし

4.2yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: COGTの 取締役会 は 経験豊富 であると考えられます ( 3.9年の平均在任期間)。